- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06206356
Lumbar Injectrode Feasibility Evaluation (LIFE)
The goal of this non-significant risk study is to determine whether stimulation with transcutaneous waveforms applied on the outside of the body and subcutaneously conducted to the lumbar medial branch nerve elicits visible (via ultrasonic imaging) or palpable multifidus muscle activation within the short-term (<28 day) placement of the Neuronoff PNS Injectrode F1 in healthy volunteers.
The main questions it aims to answer are:
- Can the PNS Injectrode F1 be safely inserted on the lumbar medial branch nerve for up to 28 days?
- Can the PNS Injectrode F1 be safely used to stimulate the lumbar medial branch nerve to activate the multifidus muscle?
Participants will
- Receive transcutaneous stimulation of the lower back prior to device placement, after device placement, and prior to explant
- Insert the PNS Injectrode F1 device on the lumbar medial branch nerve
- Have the device inserted for up to 28 days and then explanted
- Visit Schedule: Screening/Enrollment, Day 0, Day 2 (email), Day 25, 2 Days Post Explant (email), Day 35
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Morgan McGaughey
- Phone Number: 2488608403
- Email: morgan@neuronoff.com
Study Contact Backup
- Name: Jasmine Wilson
- Phone Number: 4088582612
- Email: jasmine.wilson@moxieclinical.com
Study Locations
-
-
Ohio
-
Dayton, Ohio, United States, 45458
- The Ohio Pain Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be 21 years of age or older when written informed consent is obtained.
- Literate, able to speak English and able to complete questionnaires independently.
- Willing to sign an Institutional Review Board (IRB)-approved informed consent form (ICF) and deemed capable of complying with the study requirements.
- Are currently receiving optimal medical management and considered medically stable as judged by the investigator for any significant medical condition.
- Be able to tolerate minimally invasive electrical stimulation.
- Be willing and able to understand and comply with all study-related procedures during the course of the study, and attend all scheduled study visits.
Exclusion Criteria:
- Severe cognitive impairment as determined by the Investigator.
- If female and sexually active, and the subject is not using a reliable form of birth control, is not surgically sterile or at least two years post-menopausal, the subject shall be excluded, as confirmed by the Investigator.
- If female, have a positive pregnancy test at the screening and/or Day 0 visit.
- Pre-existing motor, balance, proprioception, or sensory deficits as determined by Investigator.
- Show symptoms indicative of Covid-19 as assessed during enrollment.
- Have a skin condition at the planned surgical location.
- Have a blood coagulation disorder or other indication with the potential to impact the study biocompatibility data in unpredictable ways.
- Have a medical condition that is a contraindication for minimally invasive procedures.
- Have a cardiac demand pacemaker, implanted defibrillator or another implanted electronic device.
- Have a history of cardiac arrhythmia with hemodynamic instability.
- Be implanted with a neurostimulator.
- Have any active electrical implant of any other kind.
- Have an active infection.
- Current coagulopathy, thrombocytopenia or bleeding diathesis (confirmed by clinical history and, if clinically indicated, by coagulation screening).
- Have untreated drug habituation or dependence.
- Have uncontrolled seizures (averaging > 2 seizures per month).
- Currently require, or be likely to require, diathermy and/or MRI during study duration.
- Known hypersensitivity to any of the procedural agents or materials in the study device that is inserted into the subject.
- Have a history of adverse reactions to local anesthetics (e.g. lidocaine).
- A systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study (e.g. current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction, uncontrolled diabetes, etc.).
- Any experimental drug or device used within 30 days prior to the screening visit or during the course of the clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PNS Injectrode F1
|
The PNS Injectrode F1 is a flexible conductor that conforms to the shape of a peripheral nerve and patient anatomy.
The device is approximately 1 mm in overall diameter and is provided in lengths of 9 or 10 cm.
The device is placed in a minimally invasive procedure via a standard 18g needle.
The stimulating end of the device is placed in close proximity to the lumbar medial branch nerve with a collector end left subcutaneously.
Electrical stimulation is provided via an externally placed patch electrode connected to the provided external pulse generator over the collector end of the device.
Transcutaneous electrical stimulation will occur prior to device placement, on Day 0 after device placement, and on Day 25 prior to device removal.
Minimally invasive removal is completed by a small incision and forceps using standard medical procedures and equipment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Serious Adverse Device Effects (SADEs)
Time Frame: 35 days
|
The safety endpoint will be the percentage of subjects that experience serious adverse device effects (SADE).
|
35 days
|
Proportion of Subjects with Multifidus Muscle Activation as determined by PI via Ultrasound Imaging and Palpation
Time Frame: 25 days
|
The efficacy endpoint will be the proportion of subjects with a clinically meaningful activation of the multifidus muscle(s) unilaterally or bilaterally utilizing transcutaneous stimulation on Day 0 and on or before the Day 25 visit.
Meaningful activation will be evaluated by the PI based on ultrasonic imaging as well as palpation.
|
25 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Amol Soin, MD, MBA, The Ohio Pain Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCP-11
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Pain
-
Pain ConcernThe Thistle Foundation; Health and Social Care Alliance Scotland (the ALLIANCE) and other collaboratorsCompletedChronic Pain | Chronic Pain Syndrome | Chronic Pain, Widespread | Chronic Pain Due to Trauma | Chronic Pain Due to Malignancy (Finding) | Chronic Pain Due to Injury | Chronic Pain Post-Procedural | Chronic Pain HipUnited Kingdom
-
Consorci Sanitari de l'Alt Penedès i GarrafRecruitingChronic Post Operative Pain | Chronic Post-surgical Pain | Chronic Knee PainSpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
University of Alabama, TuscaloosaPatient-Centered Outcomes Research Institute; East Carolina University; Whatley...CompletedPain | Chronic Pain | Chronic Pain Syndrome | Widespread Chronic Pain | Chronic Pain Due to InjuryUnited States
-
University of UtahRecruitingChronic Pain | Chronic Pain Syndrome | Widespread Chronic PainUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Evolve Restorative CenterFlowonix Medical; Celéri Health, Inc.; Advanced Infusion SolutionsCompletedPain, Chronic | Pain, Intractable | Chronic Nonmalignant PainUnited States
-
Assiut UniversityNot yet recruiting
-
Vastra Gotaland RegionActive, not recruitingPain, Chronic | Widespread Chronic PainSweden
-
Washington University School of MedicineCompletedHip Pain Chronic | Back Pain | Chronic Pain | Knee Pain ChronicUnited States
Clinical Trials on PNS Injectrode F1
-
Neuronoff, IncOhio Pain ClinicCompletedChronic Lower Limb PainUnited States
-
Mansoor Aman, MDRecruitingOsteoarthritis | Osteoarthritis, KneeUnited States
-
University of Sao Paulo General HospitalFundação Faculdade de MedicinaCompleted
-
Nalu Medical, Inc.RecruitingChronic Pain | Peripheral NeuralgiaUnited States
-
The Hong Kong Polytechnic UniversityCompleted
-
Gramercy Pain CenterRecruiting
-
University of FloridaNational Institute of Nursing Research (NINR)CompletedHematopoietic Stem Cell Transplant (HSCT)United States
-
Nalu Medical, Inc.RecruitingChronic Pain | Peripheral Neuropathy | Peripheral NeuralgiaUnited States
-
Micron Medical CorporationNot yet recruitingChronic Hip Pain | Idiopathic Hip Pain
-
MiniStim LLCRecruiting